Continuing Education Activity

Acyclovir is an agent used to treat infections caused by the herpes simplex virus (HSV). Acyclovir is FDA-approved to treat genital herpes and HSV encephalitis. Non-FDA-approved indications are mucocutaneous HSV, herpes zoster (shingles), and varicella zoster (chickenpox). Acyclovir is the first-line treatment for HSV encephalitis. Currently, no other medications are indicated for treating this condition. It is in the antivirals class of drugs. This activity describes the indications, action, and contraindications for acyclovir as a valuable medication in treating HSV infections. This activity will highlight the mechanism of action, adverse event profile, and other key factors (eg, off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and clinically relevant drug interactions) pertinent to members of the interprofessional healthcare team in the management of HSV infections.

Objectives:

• Verify dosing and perform medication reconciliation when necessary.
• Strategize to reduce the potential adverse effect profile of acyclovir.
• Apply best practices when selecting and modifying treatment regimens using acyclovir.
• Collaborate with the interprofessional when initiating and monitoring acyclovir to enhance patient care.

Indications

Acyclovir is an agent used to treat infections caused by the herpes simplex virus (HSV). It is FDA-approved to treat genital herpes and HSV encephalitis. Non-FDA-approved indications are mucocutaneous HSV, herpes zoster (shingles), and varicella zoster (chickenpox).[1][2] Acyclovir is the first-line treatment for HSV encephalitis. Currently, no other medications are indicated for treating this condition.[3]

Despite the long-term use of acyclovir to treat HSV encephalitis, there has not been a systematic review regarding the efficacy of this disease/treatment combination. Current systematic reviews addressing its safety and efficacy are ongoing, with the primary outcome being the mortality rate. A secondary outcome measure is the quality of life.[4]

HSV keratitis has been shown to respond to oral acyclovir and topical steroids in pediatric patients.[5]

Stromal keratitis with ulceration caused by the herpes simplex virus can be a clinically difficult corneal infection to treat. Pisitpayat P. et al. examined the efficacy of intravenous acyclovir treatment in two patients.[6] The diagnosis was confirmed by corneal scraping samples, which underwent polymerase chain reaction (PCR) analysis. One patient had herpes simplex virus-1, and the other had herpes simplex virus-2.

The patient with herpes simplex virus-1 corneal infection initially received treatment with oral acyclovir. However, the corneal infection worsened, and the patient was switched to intravenous acyclovir. The corneal infection gradually improved. The patient with herpes simplex virus-2 corneal infection received treatment with intravenous acyclovir. The corneal infection improved. However, the patient had an epithelial lesion that required additional treatment with 100% autologous serum until the lesion healed. Both patients received prophylactic treatment with oral acyclovir to prevent corneal reinfection.

In patients with human immunodeficiency virus (HIV), acyclovir is sometimes used to treat eczema herpeticum. It is also used to prevent infections of the skin, eyes, nose, and mouth. Eczema herpeticum is rare but rapidly progressive if untreated. Those with extensive involvement, systemic symptoms, or decreased oral intake should undergo admission for intravenous acyclovir treatment.[7] Also, acyclovir treats oral hairy leukoplakia.[8][9]

Acyclovir has been proven useful in treating myelopathy secondary to varicella-zoster infection. In a small case series, researching patients from 1994 to 2014 with laboratory-confirmed varicella-zoster virus (VZV) and MRI-confirmed myelopathy, marked improvement of symptoms was the outcome in most patients within two months.[10]

Brachial plexus neuritis secondary to VZV infection and visceral disseminated VZV infection (characteristic features are abdominal and absence of skin lesions) has also responded to acyclovir, alleviating all symptoms.[11]

In recipients of hematopoietic stem cell transplantation, herpes simplex virus and varicella-zoster reactivation may respond to treatment with acyclovir prophylaxis. Prophylactic use of acyclovir should also be considered in HSV-1 and HSV-2-seropositive organ recipients.[12] Diseases from such viruses have decreased secondary to this intervention. However, a breakthrough infection may occur. Not surprisingly, HSV and VZV infection is not uncommon in patients that have discontinued acyclovir prophylaxis.[13]

Another form of prophylactic acyclovir use is juvenile-onset recurrent respiratory papillomatosis. In a prospective observational study involving 21 patients, oral acyclovir was a postoperative adjuvant. It was shown to decrease the recurrence of papillomas and thus decrease the need for successive surgeries and associated operative risks.[14]

VZV infections have many complications, including cerebellitis. Treating the source infection has also been shown to decrease the complication burden. A 2019 case report, for instance, describes a patient presenting with truncal ataxia. After intravenous acyclovir treatment, the patient was free of neurologic disability and cerebellitis. [15] Similarly, paresis secondary to dermatomal herpes zoster infections has been shown to respond to oral acyclovir; this is a rare complication of herpes zoster when the virus affects motor nerve fibers in addition to/instead of the dorsal root ganglion.[16]

Mechanism of Action

Acyclovir is an antiviral agent that incorporates itself into viral DNA, preventing further synthesis. It inhibits DNA synthesis and viral replication after converting to acyclovir triphosphate by viral and cellular enzymes. Acyclovir is a synthetic purine nucleoside analog demonstrating in vitro and in vivo inhibitory activity against both herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus.[17]

Acyclovir-resistant herpes simplex viruses (HSV) are uncommon in immunocompetent patients (< 1%), except for corneal infections. Acyclovir-resistant HSV is more common in immunocompromised patients, eg, hematopoietic stem cell transplant patients.[18]

Administration

Acyclovir administration may be oral or intravenous.

For limited mucocutaneous lesions, acyclovir administration can be via the oral route. In cases with disseminated, visceral, or CNS involvement, the acyclovir administration should be intravenous.[12]

When taken orally, acyclovir may be taken with or without food 2 to 5 times a day for 5 to 10 days and up to 12 months to prevent outbreaks of genital herpes.

Intravenous administration should be done via IV infusion only, over 1 hour, at a constant rate to prevent renal damage. Medication should be in a diluted D5W solution or 0.9% NaCl to a final concentration of less than or equal to 7 mg/mL.

The following is a non-exhaustive list of dosing regimens:

• HSV Encephalitis - 10 mg/kg IV every 8 hours for 21 days; use ideal body weight for obese patients
• Genital HSV (immunocompetent patients):

  • Mild or moderate infection, initial episode - 400 mg orally three times daily for 7 to 10 days
  • Severe infection, the first episode - 5 to 10 mg/kg IV every 8 hours for 10 days; use ideal body weight for obese patients
  • Recurring infection - 400 mg orally three times a day for 5 days. May also use 800 mg orally twice daily for 5 days 
• Genital HSV (immunocompromised patients):

  • Initial episode - 400 mg orally three times daily for 5 to 10 days
  • Recurring infection - 400 mg orally three times a day for 5 days. May also use 800 mg orally twice daily for 5 days
• Varicella-zoster - Chickenpox

  • Immunocompetent patients - 800 mg orally four to five times a day for 5 to 7 days
  • Immunocompromised patients - 800 mg orally 5 days daily for 7 days
• Varicella-zoster - Shingles

  • Immunocompetent patients - 800 mg orally five times a day for 7 days
  • Immunocompromised patients - 10 mg/kg IV every 8 hours for 7 days; use ideal body weight for obese patients

Acyclovir has poor bioavailability, which is about 10 to 20%.[19] Valacyclovir is a prodrug of acyclovir with an improved bioavailability of about 54%. Intestinal, hepatic, and renal hydrolases convert valacyclovir into acyclovir. IV-administered acyclovir demonstrates dose-independent linear pharmacokinetics.

Acyclovir plasma protein binding is low at about 15% and can penetrate the blood-brain barrier. Acyclovir is primarily renally eliminated unchanged by glomerular filtration and active tubular secretion. The mean half-life for acyclovir after I.V. administration ranges from 2.5 to 3 hours. The patient’s renal clearance correlates well with the creatine clearance.

Therefore, patient variability in the safety and efficacy of acyclovir is significantly based on the patient’s age and renal function, which requires careful monitoring. Renal impairment can dramatically increase the half-life of acyclovir, eg, up to 10 times. The pharmacokinetics of acyclovir is similar in pediatric patients. Variants in the NUDT15 and ABCC4 genes might impair the efficacy of acyclovir.

Adverse Effects

Most commonly, patients experience malaise.

Less commonly, patients experience inflammation or phlebitis at the infusion site, nausea, vomiting, transaminitis, and rash (including Steven-Johnson syndrome) when taken intravenously. Rotating infusion sites and decreasing the final infusion concentration to less than 10 mg/mL can help prevent inflammation/phlebitis at the infusion site.[20][21] Patients also may experience nausea, vomiting, diarrhea, and headache when taken orally.

Less commonly, patients experience abdominal pain, aggression/confusion, agitation, alopecia, anaphylaxis, anemia, angioedema, anorexia, ataxia, coma, disseminated intravascular coagulation (DIC), dizziness, and fatigue.

In certain pediatric patients, acyclovir has been shown to decrease hemoglobin concentrations and the absolute neutrophil count.

Brandariz-Nuñez, D. et al conducted a systemic review of neurotoxicity caused by acyclovir or its prodrug valacyclovir neurotoxicity in 119 patients (acyclovir: N = 88 and valaciclovir: N = 35).[22] The mean age of the patients was 59.5 years old. There was renal impairment in 83.3% of the patients, with 57.1% of the patients with end-stage renal disease. Based on renal function, the prescribed dose was higher than the dosing guidelines in 59.7% of the patients. Reported neurotoxicity adverse effects of acyclovir and its prodrug valacyclovir are agitation, altered consciousness, confusion, and hallucinations. The mean onset of neurotoxicity was 3.1 days (+/- 4.3 days) after the start of acyclovir or its prodrug valacyclovir, and the mean recovery time was 9.8 days (+/- 21.7 days).

Contraindications

The only absolute contraindication to acyclovir is hypersensitivity.

Cautions include renal failure/impairment, immunocompromised host, potential risk of thrombotic thrombocytopenic purpura (TTP), and hemolytic uremic syndrome (HUS).

Regarding pregnancy and lactation, acyclovir has been shown to cross the placenta. Acyclovir's manufacturer recommends caution during pregnancy and only using it when necessary and indicated, as only a few studies have been conducted. Specifically, cases of HSV hepatitis have received treatment during pregnancy.

Although rare, this condition can become disseminated and fatal in pregnant patients. Although all 56 patients studied had transaminitis, only 18.2% had a vesicular rash. For patients treated with acyclovir empirically, it conferred no risks to the fetus.[23] Acyclovir has been shown to enter breast milk but is generally considered compatible with breastfeeding.[24] 

Monitoring

Patients should be monitored for adverse effects such as malaise, inflammation or phlebitis at the infusion site, nausea, vomiting, rash (including Steven-Johnson syndrome), transaminitis, nausea, vomiting, diarrhea, headache, abdominal pain, aggression/confusion, agitation, alopecia, anaphylaxis, anemia, angioedema, anorexia, ataxia, coma, disseminated intravascular coagulation (DIC), dizziness and fatigue.

Toxicity

Acute kidney injury (AKI) is the most significant adverse effects of parenteral acyclovir administration. The incidence of AKI is comparable to other nephrotoxic medications such as aminoglycosides. Patients with CKD are at higher risk. Dose adjustment of acyclovir for ideal body weight and baseline renal function is imperative.[25] A study regarding the pharmacokinetics of acyclovir demonstrated that a patient's glomerular filtration and tubular secretion contribute to its renal excretion.[26]

Also, a recent retrospective case-control study over 4 years showed a statistically significant association between obesity and nephrotoxicity (odds ratio 3.2, 95% CI 1.19 to 8.67). Similarly, and not surprisingly, researchers observed a similar association between those receiving concomitant vancomycin (odds ratio 4.73, 95% CI, 1.57 to 14.25). Appropriate cautions are necessary when administering intravenous acyclovir to such higher-risk patients.[27]

Acyclovir treatment can cause acute kidney injury because of acyclovir crystal formation in the renal tubules. Yalçinkaya R. et al studied risk factors for acyclovir-induced acute kidney injury in children.[28] The retrospective study had a total of 472 patients. Thirty-two had acute kidney injury—most patients presented with no symptoms. Risk factors were older age, obesity, current use of nephrotoxic drugs, higher baseline creatinine concentrations, higher dose, and longer duration of acyclovir use.

Enhancing Healthcare Team Outcomes

Administering intravenous acyclovir requires interprofessional effort and communication. It is not a benign drug, having potential adverse effects such as phlebitis, hypersensitivity, and AKI. Therefore, pharmacists, prescribing clinicians (MDs, DOs, NPs, and PAs), and nurses must work together to achieve adequate and nontoxic dosing and monitor therapy.

Clinicians will make the initial decision to use acyclovir. Dose adjustments for ideal body weight and baseline renal function are necessary. The pharmacist should coordinate this with nurses and clinicians for inpatients, verifying dosing and performing medication reconciliation.

Also, patients must monitor signs/symptoms of hypersensitivity and phlebitis, specifically at the infusion site; this is where nurses will be best positioned to inform the rest of the healthcare team should there be any issues of concern. Interprofessional teamwork among each healthcare provider can help minimize and prevent the adverse effects of intravenous administration of acyclovir.[25] Interprofessional coordination and collaboration among physicians, NPs, PAs, specialists, pharmacists, nurses, and public health professionals can enhance patient outcomes when using acyclovir therapy in treating viral infections. [Level 5]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Ahronowitz I, Fox LP. Herpes zoster in hospitalized adults: Practice gaps, new evidence, and remaining questions. J Am Acad Dermatol. 2018 Jan;78(1):223-230.e3. [PubMed: 29146146]

2.

Gori N, Caldarola G, De Simone C, Moretta G, Peris K. Annular elastolytic giant cell granuloma following herpes zoster infection. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):e334-e335. [PubMed: 30980767]

3.

Stahl JP, Mailles A. Herpes simplex virus encephalitis update. Curr Opin Infect Dis. 2019 Jun;32(3):239-243. [PubMed: 30921087]

4.

Wang W, Ji M. Efficacy of acyclovir for herpes simplex encephalitis: A protocol for a systematic review of randomized controlled trial. Medicine (Baltimore). 2019 Apr;98(15):e15254. [PMC free article: PMC6485799] [PubMed: 30985731]

5.

Bodack MI. Case Series: Pediatric Herpes Simplex Keratitis. Optom Vis Sci. 2019 Mar;96(3):221-226. [PubMed: 30801497]

6.

Pisitpayat P, Jongkhajornpong P, Lekhanont K, Nonpassopon M. Role of Intravenous Acyclovir in Treatment of Herpes Simplex Virus Stromal Keratitis with Ulceration: A Review of 2 Cases. Am J Case Rep. 2021 Jun 16;22:e930467. [PMC free article: PMC8216495] [PubMed: 34133412]

7.

Ozcan A, Kahale K, Nguyen D. An 8-Month-Old Girl With Vesicular Rash. Glob Pediatr Health. 2019;6:2333794X19838526. [PMC free article: PMC6442073] [PubMed: 30956997]

8.

Ljubojević Hadžavdić S, Kovačević M, Skerlev M, Zekan Š. Genital Herpes Zoster as Possible Indicator of HIV Infection. Acta Dermatovenerol Croat. 2018 Dec;26(4):337-338. [PubMed: 30665486]

9.

Frimpong P, Amponsah EK, Abebrese J, Kim SM. Oral manifestations and their correlation to baseline CD4 count of HIV/AIDS patients in Ghana. J Korean Assoc Oral Maxillofac Surg. 2017 Feb;43(1):29-36. [PMC free article: PMC5342969] [PubMed: 28280707]

10.

Farhat N, Daoud S, Hdiji O, Sakka S, Damak M, Mhiri C. Myelopathy after zoster virus infection in immunocompetent patients: A case series. J Spinal Cord Med. 2021 Mar;44(2):334-338. [PMC free article: PMC7952078] [PubMed: 31013469]

11.

Lee S, Tsukasaki H, Yamauchi T. Visceral disseminated varicella zoster virus infection with brachial plexus neuritis detected by fluorodeoxyglucose positron emission tomography and computed tomography. J Infect Chemother. 2019 Jul;25(7):556-558. [PubMed: 30879980]

12.

Lee DH, Zuckerman RA., AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13526. [PubMed: 30859647]

13.

Dadwal SS. Herpes Virus Infections Other than Cytomegalovirus in the Recipients of Hematopoietic Stem Cell Transplantation. Infect Dis Clin North Am. 2019 Jun;33(2):467-484. [PubMed: 31005137]

14.

Mitra S, Das A, Ghosh D, Sengupta A. Postoperative Systemic Acyclovir in Juvenile-Onset Recurrent Respiratory Papillomatosis: The Outcome. Ear Nose Throat J. 2019 Jan;98(1):28-31. [PubMed: 30834790]

15.

Cross CP, English SW, Krause MA, Zalewski NL. Acute truncal ataxia in a healthy adult with varicella zoster virus cerebellitis: A case report and literature review. J Neurol Sci. 2019 May 15;400:186-187. [PubMed: 30981122]

16.

Yu YH, Lin Y, Sun PJ. Segmental zoster abdominal paresis mimicking an abdominal hernia: A case report and literature review. Medicine (Baltimore). 2019 Apr;98(15):e15037. [PMC free article: PMC6485826] [PubMed: 30985652]

17.

Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and development of inhibitors. Biochemistry (Mosc). 2014 Dec;79(13):1635-52. [PubMed: 25749169]

18.

Schalkwijk HH, Snoeck R, Andrei G. Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives. Biochem Pharmacol. 2022 Dec;206:115322. [PubMed: 36309081]

19.

Maillard M, Gong L, Nishii R, Yang JJ, Whirl-Carrillo M, Klein TE. PharmGKB summary: acyclovir/ganciclovir pathway. Pharmacogenet Genomics. 2022 Jul 01;32(5):201-208. [PMC free article: PMC9179945] [PubMed: 35665708]

20.

Le A, Patel S. Extravasation of Noncytotoxic Drugs: A Review of the Literature. Ann Pharmacother. 2014 Jul;48(7):870-886. [PubMed: 24714850]

21.

Yorulmaz A, Sahin EB, Sener M, Kulcu Cakmak S. Acyclovir-induced bullous reaction in a patient with metastatic breast cancer. Cutan Ocul Toxicol. 2017 Mar;36(1):85-87. [PubMed: 26911608]

22.

Brandariz-Nuñez D, Correas-Sanahuja M, Maya-Gallego S, Martín Herranz I. Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases. J Clin Pharm Ther. 2021 Aug;46(4):918-926. [PubMed: 34146428]

23.

McCormack AL, Rabie N, Whittemore B, Murphy T, Sitler C, Magann E. HSV Hepatitis in Pregnancy: A Review of the Literature. Obstet Gynecol Surv. 2019 Feb;74(2):93-98. [PubMed: 30756123]

24.

Charlier C, Le Mercier D, Salomon LJ, Ville Y, Kermorvant-Duchemin E, Frange P, Postaire M, Lortholary O, Lecuit M, Leruez-Ville M. [Varicella-zoster virus and pregnancy]. Presse Med. 2014 Jun;43(6 Pt 1):665-75. [PubMed: 24863663]

25.

Ryan L, Heed A, Foster J, Valappil M, Schmid ML, Duncan CJA. Acute kidney injury (AKI) associated with intravenous aciclovir in adults: Incidence and risk factors in clinical practice. Int J Infect Dis. 2018 Sep;74:97-99. [PubMed: 30048817]

26.

de Miranda P, Whitley RJ, Blum MR, Keeney RE, Barton N, Cocchetto DM, Good S, Hemstreet GP, Kirk LE, Page DA, Elion GB. Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther. 1979 Dec;26(6):718-28. [PubMed: 227639]

27.

Barber KE, Wagner JL, Stover KR. Impact of Obesity on Acyclovir-Induced Nephrotoxicity. Open Forum Infect Dis. 2019 Apr;6(4):ofz121. [PMC free article: PMC6475582] [PubMed: 31024972]

28.

Yalçınkaya R, Öz FN, Kaman A, Aydın Teke T, Yaşar Durmuş S, Çelikkaya E, Tanır G. Factors associated with acyclovir nephrotoxicity in children: data from 472 pediatric patients from the last 10 years. Eur J Pediatr. 2021 Aug;180(8):2521-2527. [PubMed: 33956193]

Disclosure: Michael Taylor declares no relevant financial relationships with ineligible companies.

Disclosure: Valerie Gerriets declares no relevant financial relationships with ineligible companies.